SCHEMBL1037757

SCHEMBL1037757

Cc1ccc(Cn2ccc3cccc(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c32)cc1

nearest known ligand 0.58

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ SLC5A2 P31639 13/20 0.58
▸ SLC5A1 P13866 8/20 0.52
▸ SLC28A3 Q9HAS3 2/20 0.47
▸ EPHX2 P34913 1/20 0.46
▸ ACHE P22303 1/20 0.45
▸ TYR P14679 1/20 0.44
▸ CD209 Q9NNX6 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1039839 0.91 SLC5A2 (0.49) SLC5A2SLC5A1SLC28A3CD209
SCHEMBL1037703 0.90 SLC5A2 (0.59) SLC5A2SLC5A1SLC28A3ACHETYR
SCHEMBL1038545 0.85 SLC5A2 (0.45) SLC5A2SLC5A1SLC28A3TYRCD209
SCHEMBL1040007 0.82 SLC5A2 (0.59) SLC5A2SLC5A1SLC28A3EPHX2ACHE
SCHEMBL1038103 0.81 SLC5A1 (0.56) SLC5A2SLC5A1SLC28A3EPHX2ACHE
SCHEMBL1038365 0.81 SLC5A2 (0.66) SLC5A2SLC5A1SLC28A3ACHETYR
SCHEMBL1036196 0.80 SLC5A2 (0.52) SLC5A2SLC5A1SLC28A3CD209
SCHEMBL13107675 0.74 SLC5A2 (0.59) SLC5A2SLC5A1SLC28A3ACHE
SCHEMBL4350700 0.74 SLC5A2 (1.00) SLC5A2SLC5A1EPHX2
SCHEMBL2577336 0.74 SLC5A2 (1.00) SLC5A2SLC5A1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1849795-B1 1-SUBSTITUTED-7-( -D-GLYCOPYRANOSYLOXY)(AZA)INDOLE COMPOUND AND PHARMACEUTICAL CONTAINING THE SAME KISSEI PHARMACEUTICAL (JP) 2011-01-26 — — EP claimed
EP-1849795-B1 1-SUBSTITUTED-7-( -D-GLYCOPYRANOSYLOXY)(AZA)INDOLE COMPOUND AND PHARMACEUTICAL CONTAINING THE SAME KISSEI PHARMACEUTICAL (JP) 2011-01-26 — — EP disclosed
US-7749972-B2 1-substituted-7-(β-D-glycopyranosyloxy)(aza)indole compound and pharmaceutical containing the same KISSEI PHARMACEUTICAL CO., LTD. (JP) 2010-07-06 — — US disclosed
US-7749972-B2 1-substituted-7-(β-D-glycopyranosyloxy)(aza)indole compound and pharmaceutical containing the same KISSEI PHARMACEUTICAL CO., LTD. (JP) 2010-07-06 — — US disclosed
US-7749972-B2 1-substituted-7-(β-D-glycopyranosyloxy)(aza)indole compound and pharmaceutical containing the same KISSEI PHARMACEUTICAL CO., LTD. (JP) 2010-07-06 — — US disclosed
US-20090054356-A1 1-SUBSTITUTED-7-(B-D-GLYCOPYRANOSYLOXY)(AZA)INDOLE COMPOUND AND PHARMACEUTICAL CONTAINING THE SAME KISSEI PHARMACEUTICAL CO., LTD. (JP) 2009-02-26 — — US disclosed
US-20090054356-A1 1-SUBSTITUTED-7-(B-D-GLYCOPYRANOSYLOXY)(AZA)INDOLE COMPOUND AND PHARMACEUTICAL CONTAINING THE SAME KISSEI PHARMACEUTICAL CO., LTD. (JP) 2009-02-26 — — US disclosed
US-20090054356-A1 1-SUBSTITUTED-7-(B-D-GLYCOPYRANOSYLOXY)(AZA)INDOLE COMPOUND AND PHARMACEUTICAL CONTAINING THE SAME KISSEI PHARMACEUTICAL CO., LTD. (JP) 2009-02-26 — — US disclosed
EP-1849795-A1 1-SUBSTITUTED-7-( -D-GLYCOPYRANOSYLOXY)(AZA)INDOLE COMPOUND AND PHARMACEUTICAL CONTAINING THE SAME Kissei Pharmaceutical Co., Ltd. (JP) 2007-10-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054356-A1 1-SUBSTITUTED-7-(B-D-GLYCOPYRANOSYLOXY)(AZA)INDOLE COMPOUND AND PHARMACEUTICAL CONTAINING THE SAME SLC5A1, SLC5A2, GPR119 SLC5A2 2/4885SLC5A1 1/4885SLC28A3 539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback